Eric Adler

Eric Adler, MD, joined LEXEO Therapeutics in 2022 as Chief Scientific Officer. Dr. Adler is a pioneer in cardiovascular gene therapy, and currently serves as Professor of Medicine, head of the Heart Failure Section, Director of the Strauss Center for Cardiomyopathy, and the Czarina and Humberto S. Lopez Chancellor's Endowed Chair in Cardiology at the University of California, San Diego (UCSD). Dr. Adler's work has led to the development of a novel investigational gene therapy for Danon disease, which is currently in Phase 1 clinical development, and he serves on multiple advisory boards, including Rocket Pharmaceuticals, lonis Pharmaceuticals, and Sana Biotechnology Dr. Adler's research is focused on the study and treatment of cardiomyopathy and he has published over 100 papers in peer-reviewed journals on the topic. Dr. Adler is currently an associate editor of Circulation Heart Failure, and has served on leadership grant review, and guideline committees for the American Heart Association, the Heart Failure Society of America, the International Society of Heart and Lung Transplant, and the National Institute of Health.

Dr. Adler earned his medical degree from the Boston University School of Medicine.